The obesity research experts recently termed a weight-loss drug as the “Game Changer.” This drug has just been approved by the US Food and Drug Administration (FDA). Thus, for the first time, this has represented the agency to endorse such a treatment in several years.
Wegovy is a weight management therapy developed by Danish pharmaceutical company Novo Nordisk. Notably, this is the first FDA-approved weight-loss drug since 2014. However, Wegovy not an entirely new medication. Also, Semaglutide, a drug similar to Wegovy is being used by the masses of the US and other countries.
Significantly, this drug is an anti-diabetic medication for the last many years. Although, recent shreds of evidence also clarified that the dug Semaglutide at a different level of dosage also functions as a powerful and effective appetite-suppressant. Yet, Novo Nordisk has not confirmed the price of this drug. However, there are indications the company may charge US$1,300 per month.
Rachel Batterham, an obesity researcher from University College London said, “No other drug has come close to producing this level of weight loss – this really is a game-changer.” He further mentioned that for the first time, people can achieve through drugs what was only possible through weight-loss surgery.”
Few of the individuals suffering from obesity also lost even more. Thus, with over 30 percent of the group dropping in excess of 20 percent of their body weight. These results signify that the scientists singled out as remarkable. These discomforts were enough for some in the group to stop the treatment. But for many people, who do not experience any of the side effects or grimaced through them, potentially life-transforming weight loss was achievable.
Another obesity expert, Robert Kushner from Northwestern University said, “This is the first time we have seen this magnitude of weight loss with a medicine. This approval gives people with obesity a once-weekly, non-surgical option with results that have never been demonstrated with an anti-obesity medicine before.”